Autolus (AUTL) Q2 2026 Earnings Call Transcript

Autolus (AUTL) reported Q2 2026 net product revenue of $45.7M, up 119% YoY, and raised full-year guidance to $140M-$150M. Gross margin improved to 55%, and cash runway extends into Q2 2028. The company expanded treatment centers and saw initial U.K. sales.

Original reporting
Published Aug 18, 2026, 5:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 5:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Autolus (AUTL) Q2 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$AUTLBullishMed
01

Why it matters

The most tradable elements are the raised FY 2026 revenue guidance, the gross margin step-up, and the explicit funding runway extension via the Perceptive credit facility plus milestone-based tranches.

02

Market read

Traders can update valuation assumptions around growth rate, gross margin trajectory, and balance-sheet risk after the guidance raise and cash runway extension.

03

What to watch

R&D and SG&A are rising (R&D $27.9M, SG&A $41.2M), and the pipeline catalysts (BOBCAT, CATULUS, ALARIC) are still dated into 2027-2028, leaving near-term upside dependent on continued center activation and demand.

Relevance 8/10Novelty 8/10Timing: after-hours/next-session repricing following the Q2 2026 earnings call

Background

Autolus held its Q2 2026 financial results conference call, covering commercial performance of AUCATZYL and updates across its clinical pipeline and financing.

Company-level read

Ticker impact

$AUTLBullishMedium confidence
Context

Autolus raised FY 2026 guidance to $140M-$150M and reported Q2 net product revenue of $45.7M, plus gross margin expansion to 55%.

Expected impact

Likely positive bias for the stock into the next few sessions as traders reprice growth and margin inflection, tempered by ongoing commercialization and clinical spend.

Evidence & confidence

The call includes multiple decision-relevant datapoints: raised revenue guidance, a step-change in gross margin, and explicit cash runway into 2Q28 supported by a credit facility and milestone-based tranches.

Market effects

Supports the broader CAR-T commercialization narrative by highlighting center expansion, manufacturing fixed-cost absorption, and margin progression.

UK launch traction is early but provides a measurable international expansion datapoint for investors tracking US-to-UK scaling.

Reinforces investor appetite for cell therapy names with improving unit economics and extended funding runway.

Counterpoint

Margin improvement may be partly volume-driven and could reverse if manufacturing automation or batch economics do not deliver as planned.

Key entities

  • Autolus Therapeutics

    Subject of the earnings call, reporting Q2 results, raised FY 2026 guidance, margin expansion, and financing/cash runway details.

  • AUCATZYL (obe-cel)

    Autolus' CD19-targeting CAR T therapy, driving net product revenue growth and center expansion.

  • Perceptive Advisors credit facility

    Up to $250M aggregate principal with an initial $75M drawn and additional tranches tied to revenue milestones.

Related articles

$AUTLHighAI 8/10

Autolus (AUTL) Q3 2026 Earnings Call Transcript

Autolus (AUTL) reported Q3 2026 earnings, raising full-year revenue guidance to $150M+. Net revenue grew 95% YoY to $41.2M, with gross margins improving to 57%. The company expects to fund operations into Q2 2028. AUCATZYL's performance and manufacturing efficiency drove results. Clinical trials for AUCATZYL, AUTO8, and other pipeline products are progressing, with data presentations planned for upcoming conferences.

$AUTLHigh

Autolus Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates November 10, 2026 at 7:00 AM EST Company reports AUCATZYL®…

Autolus Therapeutics plc (AUTL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Autolus Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates November 10, 2026 at 7:00 AM EST Company reports AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $41.2 million, an increase of 95% year-over-year; now expects full-year 2026

$AUTLMedAI 8/10

AUCATZYL Sales Are Exploding, But Autolus (AUTL) Still Isn’t In The Black

Autolus Therapeutics (AUTL) reported Q2 2026 revenue of $45.7M, up 119% YoY, driven by AUCATZYL sales. The company raised full-year guidance to $140M-$150M and secured a $250M credit facility. Despite improved margins, Autolus posted a $39.1M net loss and cash decreased to $201.6M. AUCATZYL carries significant safety warnings, and $150M of financing is tied to revenue milestones.